Administration of CD19-CAR T cells leads to near complete eradication of CD19+ malignant and B cell lineage cells in patients with advanced lymphomas (9–14) and multiple forms of chemo-refractory or advanced leukemias (15–23). This evidence concerns the gene CD19 and leukemia.